Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

venetoclax 91Azacitidine 75Cytarabine 68Specimen Handling 45fludarabine 44Biopsy 32Cyclophosphamide 29Daunorubicin 27fludarabine phosphate 25Injections 25Decitabine 25Idarubicin 24Busulfan 20Granulocyte Colony-Stimulating Factor 19Whole-Body Irradiation 18Mycophenolic Acid 18Tacrolimus 17Melphalan 17decitabine and cedazuridine drug combination 16gilteritinib 14Stem Cell Transplantation 14CPX-351 14Mitoxantrone 13Peripheral Blood Stem Cell Transplantation 11Magnetic Resonance Spectroscopy 11Filgrastim 11Etoposide 11Cladribine 11ivosidenib 10revumenib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Myeloid, Acute × voruciclib × 90 days × Clear all
NCT03547115 2026-03-17

A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML

MEI Pharma, Inc.

Phase 1 Terminated
84 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡